Hypothesis

Core idea: We'll test the idea that simultaneous inhibition of NLRP3 inflammasome activity in thymic epithelial cells and blockade of IL‑6 trans‑signaling in peripheral macrophages will break the self‑reinforcing loop that links thymic atrophy to inflammaging, thereby restoring youthful immune output and delaying multi‑organ decline.

Mechanistic rationale

1. NLRP3 activation in thymic stroma senses lipid danger signals (cholesterol, ceramides) → caspase‑1 cleavage → IL‑1β release → epithelial damage and reduced T‑cell progenitor output (source).
2. Damaged thymic epithelial cells release mitochondrial DNA into the extracellular space, activating the cGAS‑STING pathway in neighboring cells. This pathway drives NF‑κB–dependent transcription of IL‑6, linking innate inflammasome signaling to cytokine production.
3. It's known that elevated IL‑6 acts on macrophages via trans‑signaling (IL‑6R/sIL‑6R/gp130) to suppress their capacity to produce TNFα, IL‑1β and IL‑12 upon infection, fostering a permissive environment for senescent cell accumulation (source).
4. The resulting cytokine milieu further promotes lipid accumulation in thymic epithelium, completing a feed‑forward loop that accelerates both thymic involution and peripheral myeloid dysfunction.

Novel insight

We propose that the cGAS‑STING axis is the molecular bridge converting NLRP3‑driven mitochondrial stress into IL‑6 overproduction. Pharmacological or genetic interruption of cGAS‑STING should therefore attenuate IL‑6 rise even when NLRP3 remains active, and conversely, IL‑6 blockade should lower lipid uptake in thymic epithelium via reduced STAT3‑mediated SREBP1 activation. We don't expect either intervention alone to fully reset the loop, but together they should.

Testable predictions

• Genetic: Mice with thymic‑epithelial‑specific Nlrp3 deletion (Foxn1‑Cre; Nlrp3fl/fl) will show reduced mtDNA release, lower cGAS‑STING activation, and decreased IL‑6 transcripts in thymus compared with wild‑type aged controls.
• Pharmacologic: Treatment of aged mice with a thym‑targeted NLRP3 inhibitor (e.g., MCC950 conjugated to a fibroblast‑activation‑protein agonist) plus an IL‑6 trans‑signaling blocker (sgp130Fc) will:
  • Increase naïve T‑cell output (measured by TCR excision circles) by ≥2‑fold.
  • Restore macrophage TNFα and IL‑12 production after LPS challenge to ≥80 % of young levels.
  • Decrease circulating senescence markers (p16^INK4a^, SASP factors) by ≥30 %.
  • Extend median lifespan by ~15 % and improve frailty index scores.
• Falsifiable: If combined treatment fails to improve either thymic output or macrophage function despite target engagement (confirmed by drug‑specific biomarkers), the hypothesis that NLRP3‑IL‑6 crosstalk drives immunosenescence is refuted.

Experimental outline

| Group | Intervention | n (per sex) | Primary readouts | |-------|--------------|------------|------------------| | 1 | Vehicle control | 15 | Baseline | | 2 | Thym‑NLRP3 inhibitor alone | 15 | Thymic cellularity, IL‑6 | | 3 | IL‑6 trans‑signaling blocker alone | 15 | Macrophage cytokine output | | 4 | Combination therapy | 15 | All readouts + lifespan | | 5 | Young untreated (reference) | 10 | Youthful benchmarks |

Measurements at 3, 6, 12 months: flow cytometry for CD4^+CD8^+ double‑positive thymocytes, qPCR for Nlrp3, Casp1, Il6, Cgas, Sting; ELISA for serum IL‑6, IL‑1β; ex‑vivo macrophage stimulation; frailty assessment (grip strength, gait speed); survival monitoring.

Potential impact

If validated, this approach would demonstrate that re‑programming two interconnected immune checkpoints can reset the inflammaging clock, offering a unified strategy to delay age‑related pathology without the need for broad senolytics or hematopoietic replacement.